

Standard Operating Procedures of *ICMR-NIRRCH Ethics Committee for Human Studies*

SOP- Version 7,
8th November 2024



icmr | NIRRCH
INDIAN COUNCIL OF MEDICAL RESEARCH | NATIONAL INSTITUTE FOR RESEARCH
IN REPRODUCTIVE AND CHILD HEALTH

**National Institute For Research In
Reproductive and Child Health**

Accreditation and Registrations

The ICMR-NIRRCH Ethics Committee for Human Studies has been recognized by

- **Strategic Initiative for Developing Capacity in Ethical Review - Forum for Ethical Review Committees in Asia and the Western Pacific Region (SIDCER – FERCAP) in 2014 and re-recognized in 2017 and 2021.**

The following national and international agencies recognize the ICMR-NIRRCH ethics committee for Human Studies

- **Central Drugs Standard Control Organization (CDSCO)**
- **Department of Health Research (DHR)**
- **Office for Human Research Protections (OHRP)**



The Strategic Initiative for Developing Capacity in Ethical Review



in collaboration with the



Forum for Ethical Review Committees in Asia and the Western Pacific Region

hereby renews recognition of the

**National Institute for Research in Reproductive Health
(NIRRH) Ethics Committee for Clinical Studies,
Indian Council of Medical Research (ICMR)
(Mumbai, India)**

for its compliance with the
Declaration of Helsinki, International Conference on
Harmonization (ICH) Guidelines, Good Clinical Practice (GCP)
Standards, Council for International Organizations of Medical
Sciences (CIOMS) Guidelines, World Health Organization
(WHO) Standards and Operational Guidance for Ethics Review
of Health-Related Research and Surveying and Evaluating
Ethical Review Practices, EC/IRB Standard Operating
Procedures (SOPs), and Local Regulations and Standards in
Ethical Review

Awarded during the 17th FERCAP General Assembly
in New Delhi, India on November 22, 2017

JUNTRA KARBWANG
SIDCER Coordinator

KENJI HIRAYAMA
FERCAP Chair

The Strategic Initiative for Developing Capacity in Ethical Review



in collaboration with the



Forum for Ethical Review Committees in Asia and the Western Pacific Region

hereby renews recognition of the

National Institute for Research in Reproductive & Child Health (ICMR-NIRRH) Ethics Committee for Human Studies (Mumbai, India)

for its compliance with the
Declaration of Helsinki, International Council for Harmonisation
(ICH) Guidelines, Good Clinical Practice (GCP) Standards,
Council for International Organizations of Medical Sciences
(CIOMS) Guidelines, World Health Organization (WHO)
Standards and Operational Guidance for Ethics Review of
Health-Related Research and Surveying and Evaluating Ethical
Review Practices, EC/IRB Standard Operating Procedures
(SOPs), and Local Regulations and Standards in Ethical Review

Awarded during the 21st FERCAP General Assembly
in Yogyakarta, Indonesia (via Zoom) on December 11, 2021

JUNTRA KARBWANG
SIDCER Coordinator

KENJI HIRAYAMA
FERCAP Chair

Background

ICMR-NIRRH Ethics Committee for Human Studies is an independent body constituted of non-affiliated Chairperson along with varied affiliated as well as non-affiliated members from medical, non-medical, scientific, non-scientific, legal & social-science backgrounds whose responsibility is to ensure the protection of the rights, safety, and well-being of human subjects involved in the research/ trial, by reviewing, approving and providing a continuing review of the research protocols and amendments. It ensures the effective implementation of National & International Ethical guidelines for researchers engaged in Clinical, Biomedical, Operational & Implementation Research that involves Human Study participants.

The Ethics Committee for Clinical Studies involving Human Participants was established in the Institute for Research in Reproduction (formerly known as IRR) in October 1994. In February 2022 the NIRRH Ethics Committee for Clinical Studies was renamed as ICMR-NIRRH Ethics Committee for Human Studies.

The first version of the IEC's standard operating procedures (SOP) was prepared in 2014. It helped standardize procedures and lay a sound foundation for the day-to-day practices of our institute's conduct of ethical research. The SOP is revised periodically to ensure compliance with the evolving guidelines.

The review process ensures that the documents are submitted to the IEC secretariat at least 3 to 4 weeks before IEC meeting. IEC Secretariat checks for the completeness of the project proposal concerning the information, methodology, informed consent documents, and signatures of the Principal and Co-Investigator/ Collaborators along with the necessary scientific review/ approval. The member secretary then assigns the project to appropriate reviewers (Expertise as per the subject of the Research Project) & the documents are mailed to the reviewers at least 10 days before the meeting date.

The following criteria are considered while reviewing the study protocol:

- Minimize risks to participants
- Participants are selected equitably
- Risks must be reasonable concerning anticipated benefits Informed consent is adequate, easy to understand, and properly documented
- There are adequate provisions to protect the privacy of participants and to maintain the confidentiality of data, where appropriate;
- Appropriate safeguards are included to protect vulnerable participants.
- Informed consent is appropriate, easy to understand, and properly documented
- The research plan makes adequate provision for monitoring the data collected to ensure the safety of participants, where appropriate;
- Ensure that the research project does not induce the participants to be lured into the research/ clinical trials and that the researcher has a recruitment policy to ensure an unbiased selection of an adequate number of suitable participants according to the protocol

Prof. Shubhada Chiplunkar

Former Director ACTREC-TMC

Preface

With immense pleasure, I write the preface for the revised edition (Version 7.0) of the SOPs (Standard Operating Procedures) for IEC. The ICMR-NIRRH Ethics Committee for Human Studies serves a great purpose in effectively implementing Ethical guidelines for researchers engaged in Clinical, Biomedical, Operational, and Implementation Research involving Human Study participants.

.Dr. Ragini Kulkarni, former Member Secretary, and Dr. Usha Saraiya, former Chairperson of IEC, NIRRH, Mumbai, spearheaded the creation of the First Edition of SOPs in 2014. Subsequently, Dr. Beena Joshi, former Member Secretary, and Dr. Padmavathy Menon, former Chairperson, led the development of the updated edition.

This comprehensive document covers the entire mandatory requirement as per the regulatory guidelines. Faculty and researchers at the institute found it beneficial to submit it to the IEC for approval. The Director of ICMR-NIRRH, Mumbai, also appreciated the effort, noting that it was well-received by the researchers and scientists of NIRRH over time.

The need to update the SOPs arose due to evolving global requirements and new guidelines led by the ICMR Bioethics division. A core team consisting of a Member Secretary and two Ethics Members with thorough knowledge of ethics was formed to draft the revised SOPs.

In-depth deliberation and inputs from the SOP team members have led to a revision of SOPs. The draft SOPs were circulated to members of the IEC for their input. On record, I would like to sincerely thank the core group members for drafting revised SOPs, members of IEC, and distinguished researchers & scientists of ICMR-NIRRH for their valuable inputs. Director, ICMR-NIRRH, Dr. Geetanjali Sachdeva also gave useful inputs for which she deserves appreciation. Special thanks to Dr. Vikrant Bhor, Member Secretary, IEC, Dr. Bhakti Pathak, Jt. Member Secretary Dr. Suchitra Surve, Ex.Jt. Member Secretary, IEC, and Dr. Beena Joshi, Ex-Member Secretary, IEC for revision of SOPs.

The document is now ready for release. The updated SOPs are user-friendly and will help researchers and scientists at ICMR-NIRRH submit their proposals to the IEC for approval.



(Dr. Shubhada Chiplunkar)

Chairperson, IEC, ICMR-NIRRH, Mumbai

Dated: 8.11.2024

Place: Mumbai

Acknowledgment

The NIRRCH Ethics Committee for Human Studies involving human participants was established in 1994. To date, six ethics committees have been functional following national and international guidelines for research involving human participants. At the outset, we express gratitude and acknowledge the contributions of all our previous Ethics committee members for the smooth functioning of our IEC.

The first version of the SOP was constituted in 2014 which helped us standardize procedures and lay a sound foundation for the ethics practices in research at our Institute. We gratefully acknowledge the contributions of the SOP team for revising the SOPs.

We extend our heartfelt thanks to Dr. Ragini Kulkarni and Dr. Beena Joshi, former IEC member secretaries for their significant contributions, time, and effort in formulating and revising the SOPs.

The administrative support extended by Mrs. Zakia Ansari, Ex-Secretariat staff Mrs. Vaishali Bhogate, and Mr. Sasikumar is duly recognized.

We especially thank the IEC Chairperson, Dr. Shubhada Chiplunkar, and Ex-Chairperson, Dr. Padmavathy Menon for their guidance and valuable input. We are grateful to the Director, ICMR-NIRRCH, Dr. Geetanjali Sachdeva, for her continued guidance and support.

The revised SOPs have some major modifications, especially in the project submission forms, guidelines, and timelines for submitting and reporting to the IEC, references to websites for new guidelines on various aspects of ethics in research, and a new chapter on on-site monitoring and post-monitoring activities.

We hope that these revised SOPs for the functioning of the IEC will be useful in upholding the procedures for conducting ethical practices in research at the Institute.



Dr. Vikrant Bhor
Member Secretary
IEC, ICMR-NIRRCH, Mumbai



Dr. Bhakti Pathak
Joint Member Secretary
IEC, ICMR-NIRRCH, Mumbai

Contents

Sr. No.	Titles		SOP Code	Page No.
	List of Abbreviations			
	Bibliography			
	Glossary			
A	Preparation of SOPs for ICMR – NIRRH Ethics Committee for Human Studies and Guidelines for Ethics Committee			
1. Writing, Reviewing, Distributing and Amending SOPs			01/ V1.6	5-10
1.1	Purpose			6
1.2	Scope			6
1.3	Responsibility			6
1.4	Flowchart			7
1.5	Detailed Instructions			7
	1.5.1	Appoint the SOP Team		7
	1.5.2	List all relevant SOPs		7
	1.5.3	Format and layout		7
	1.5.4	Design the format		8
	1.5.5	Write the SOP and approve new SOP		8

	1.5.6	Implement, distribute, and file all SOPs	9
	1.5.7	Review and request for a revision of an existing SOP	9
	1.5.8	Manage and archive OBSOLETE SOPs	9
1.6	Annexures		10
AF/01/01/V1.6	List of SOPs		11
AF/01/02/V1.6	Template for SOP		12
AF/01/03/V1.6	Document History template		13
AF/01/04/V1.6	Log of SOP Recipients		13
AF/01/05/V1.6	Request for Revision of an SOP		14
AF/01/06/V1.6	Document History		15
B	Constituting the Ethics Committee for Research on Human Participants		
2. Constitution of an IEC		02/V1.5	16-30
2.1	Purpose		17
2.2	Scope		17
2.3	Responsibility		17
2.4	Flowchart		17
2.5	Detailed Instructions		18
	2.5.1	Ethical basis and mandate	18
	2.5.2	Composition of IEC	19

	2.5.3	Membership requirements	20
	2.5.4	Resignation, Disqualification, Replacement of Members	21
	2.5.5	Independent Consultants	21
	2.5.6	Conditions of Appointment	22
	2.5.7	Officers and their responsibilities	22-25
	2.5.8	Secretariat	26
	2.5.9	Roles and Responsibilities of IEC Members	27
	2.5.10	Quorum Requirement of EC Meetings	27
	2.5.11	Dissolving of the IEC	28
2.6	Annexures		28
AF/01/02/V1.5	Document History		29-30
3. Confidentiality/Conflict of Interest Agreement			03/V1.3
3.1	Purpose		32
3.2	Scope		32
3.3	Responsibility		32
3.4	Flowchart		32
3.5	Detailed Instructions		33
	3.5.1	Read the text carefully and thoroughly	33

	3.5.2	Ask questions, if any	33
	3.5.3	Sign with consent.	33
	3.5.4	Keep the Agreement in mind	34
3.6	Annexures		34
AF/01/03/V1.3	Confidentiality Agreement Form for Ethics committee members/ Secretariat staff		35-36
AF/02/03/V1.3	Conflict of Interest Agreement Form for Ethics Committee Members		37
AF/03/03/V1.3	Confidentiality Agreement Form for Guest Attendees to IEC-ICMR-NIRRH Meetings		38
AF/04/03/V1.3	Confidentiality Agreement Form for Independent Consultants		39
AF/05/03/V1.3	Confidentiality Agreement for Non-members Requesting Copy (ies) of IEC Documents		40
AF/06/03/V1.3	Log of Requests for Copies of IEC Documents		41
AF/07/03/V1.3	Log of Requests for Original Documents		41
AF/08/03/V1.3	Document History		41
4. Training Personnel and Ethics Committee Members		04/V1.2	42-45
4.1	Purpose		43
4.2	Scope		43
4.3	Responsibility		43
4.4	Flowchart		43
4.5	Detailed Instructions		43

	4.5.1	Topics for training	43
	4.5.2	How to get trained	44
4.6	Annexures		45
AF/01/04/V1.2	Document History		45
5. Selection and Responsibilities of Independent Consultants			05/V1.2
5.1	Purpose		47
5.2	Scope		47
5.3	Responsibility		47
5.4	Flowchart		47
5.5	Detailed Instructions		47
	5.5.1	Selection and Appointment of Independent Consultants (ICs)	47
	5.5.2	Co - ordination with Independent Consultants for fulfilling administrative requirements	48
	5.5.3	Reading, understanding and signing the Conflict-of-Interest document and Confidentiality Agreement	48
	5.5.4	Consultation Services	48
	5.5.5	Termination of the Services	48
5.6	Annexure		49
AF/01/05/V1.2	Document History		49

C		Protocol Submission Procedures	
6. Templates for protocol & other submissions		06/V2.2	50-130
6.1	Purpose		51
6.2	Scope		51
6.3	Responsibility		51
6.4	Annexures		51-52
AF/1/06/V2.2	Lists of Applications to be attached for Initial Review of project (Checklist)		53-55
AF/1.1/06/V2.2	Application form for Initial Review		56-70
AF/1.2/06/V2.2	Format for Technical summary and Detailed Protocol		71
AF/1.3/06/V2.2	Guidelines for reviewing PIS and ICD		72-76
AF/1.4/06/V2.2	PIS For Study Participants/Parents of children who would participate in the study		77-79
AF/1.5/06/V2.2	Informed Consent Form (ICF)		80
AF/1.6/06/V2.2	Informed Consent Form For permitting to take a photograph		81
AF/1.7/06/V2.2	Informed Consent Form For future use of stored samples		82
AF/1.7A/06/V2.2	Informed Consent Form For future use of research data		83
AF/1.8/06/V2.2	Assent Information Sheet		84-86
AF/1.8A/06/V2.2	Oral Assent Information Sheet		87-89
AF/1.9/06/V2.2	Assent Consent Form		90
AF/1.10/06/V2.2	Parental/LAR Consent Form		91
AF/1.11/06/V2.2	Undertaking format to be submitted by the Principal Investigator/ Research Guide		92

AF/1.12/06/V2.2	Undertaking format for using stored samples and data from other projects	93
AF/1.13/06/V2.2	Draft of MoU/ MTA	94-98
AF/1.14/06/V2.2	Format for Curriculum Vitae for Investigators	99
AF/2.0/06/V2.2	Application form for Clinical Trials	100-103
AF/2.1/06/V2.2	Guide to Placebo Justification	104-106
AF/3/06/V2.2	Application Form for Human Genetics Testing Research	107-108
AF/4/06/V2.2	Application Form for Socio-Behavioural & Public Health Research	109-110
AF/5/06/V2.2	Application Form for Exemption from Ethical Review	111-112
AF/5.1/06/V2.2	Undertaking by Principal Investigator along with Request for Exemption from Ethical Review (Check SOP 10 for details)	113
AF/6/06/V2.2	Application Form for Expedited Review (Check SOP 11 for details)	114-115
AF/7/06/V2.2	Application/Notification form for Amendments (Check SOP 14 for details)	116-117
AF/8/06/V2.2	Continuing Review Report format (Check SOP 15 for details)	118-120
AF/9/06/V2.2	Request for Extension of approved study (Check SOP 15 for details)	121
AF/10/06/V2.2	Study Completion/Final report format (Check SOP 16 for details)	122-123
AF/11/06/V2.2	Premature Termination/Suspension/ Discontinuation Report Format (Check SOP 17 for details)	124-125
AF/12/06/V2.2	Information on what to expect after Protocol Submission	126-128
AF/13/06/V2.2	Document History	129-130
D	Vulnerable Populations	

7. Vulnerable Populations		07/V1.5	131-137
7.1	Purpose		132
7.2	Scope		132
7.3	Responsibility		132
7.4	Flow Chart		132
7.5	Detailed Instructions		133
	7.5.1	Determine protocols including vulnerable population	133
	7.5.2	Vulnerable groups	134
	7.5.2.1	Consideration issues and protection of specific vulnerable groups	134-136
7.6	Annexures		136
AF/01/07/V1.5	Document History		137
E	Audio-Visual (AV) Recording of Informed Consent Process		
8. Audio-Visual (AV) Recording of Informed Consent Process		08/V1.5	138-147
8.1	Purpose		139
8.2	Scope		139
8.3	Responsibility		139
8.4	Applicable rules, regulations and guidelines		140
8.5	Detailed Instructions		140-141

8.6	Annexure	142
AF/01/08/V1.4	Checklist for Monitoring of Audiovisual recording of AV consent Process	143-146
AF/02/08/V1.4	Document History	147
F	Management of Protocol Submissions	
9. Management of Protocol Submissions		09/V1.7
9.1	Purpose	149
9.2	Scope	149
9.3	Responsibility	149
9.4	Flowchart	149
9.5	Detailed Instructions	150
	9.5.1	Receive submitted documents
	9.5.1.1	Initial Review Application
	9.5.1.2	Resubmission of Protocols with Corrections
	9.5.1.3	Protocol Amendment
	9.5.1.4	Continuing Review of Approved Protocols including AE/SAE
	9.5.1.5	Protocol Termination/ Suspension/ Discontinuation
	9.5.1.6	Request for extension of Approved Protocols
	9.5.1.7	Project Completion/ Final

	9.5.2	Check for submission items	151
	9.5.2.1	Check the submitted documents	151
	9.5.2.1.1	Initial Review	151
	9.5.2.1.2	Resubmission of Protocols with corrections	152
	9.5.2.1.3	Protocol Amendments	152
	9.5.2.1.4	Continuing Reviews of Approved Protocols	152
	9.5.2.1.5	Protocol Termination/ Suspension/ Discontinuation	153
	9.5.2.1.6	Request for extension of Approved Protocols	153
	9.5.2.1.7	Protocol Completion/ Final	153
	9.5.2.1.8	Management of disapproved protocol	153
	9.5.2.2	Fill in the forms	154
	9.5.2.3	Verify contents of submitted project proposal	154
	9.5.3	Complete the Checking process	154
	9.5.4	Processing the submitted documents	154
	9.5.5	Create a Protocol Specific File (for Initial Review)	154
	9.5.6	Store the received documents	155
	9.5.7	Timelines for Procedures	155
9.6	Annexures		155
AF/01/09/V1.7	Approval Letter		156
AF/02/09/V1.7	Document History		157-159

G		Review of Submitted Protocols	
10. Exempt from ethical review		10/V1.3	160-166
10.1	Purpose		161
10.2	Scope		161
10.3	Nature of Study Proposals considered exempt from ethical review process		161
10.4	Flowchart		161
10.5	Detailed Instructions		162
	10.5.1	Receive the submitted documents	162
	10.5.2	Determinate protocols for exempt from ethical review	162
	10.5.3	Exempt Process	163
	10.5.4	Communicate the decision to the investigator and IEC Members	164
10.6	Annexures		164
AF/01/10/V1.1	Approval letter for Exempt Review		165
AF/02/10/V1.1	Document History		166
11. Expedited Review		11/V3.4	167-173
11.1	Purpose		168
11.2	Scope		168
11.3	Nature of Study Proposals considered for expedited review		168
11.4	Flowchart		169

11.5	Detailed Instructions		169
	11.5.1	Receive the submitted documents	169
	11.5.2	Determinate protocols for expedited review	169
	11.5.3	Expedited Process	170
	11.5.4	Communicate the decision to the investigator and IEC Members	171
11.6	Annexures		171
AF/01/11/V3.4	Approval letter for Expedited Review		172
AF/02/11/V3.4	Document History		173
12. Initial Review of Project Proposal			12/2.1 174-187
12.1	Purpose		175
12.2	Scope		175
12.3	Responsibility		175
12.4	Flow Chart		175
12.5	Detailed Instructions		175
	12.5.1	Choosing primary reviewers and roles of the assigned primary reviewers	175
	12.5.2	Decision-making on submitted protocols	176-177
	12.5.3	Final communication of the Ethics Committee decision taken on the project to the Principal Investigator	178
12.6	Annexures		179
AF/01/12/V2.1	Study Assessment Form		180-184
AF/02/12/V2.1	Project Review Form		185
AF/03/12/V2.1	Document history		186-187

H	Review of Protocol Revision and Amendment, Continuing Review Report and Completion Report		
13. Review of Resubmitted Protocols		13/V1.4	188-192
13.1	Purpose		189
13.2	Scope		189
13.3	Responsibility		189
13.4	Flowchart		189
13.5	Detailed Instructions		189
	13.5.1	Receive protocol resubmitted package	189
	13.5.2	Review the revised protocol at the Secretariat level	190
	13.5.3	IEC meeting	190
	13.5.4	Written Communication of the Decision	191
13.6	Annexures		191
AF/01/13/V1.3	Document History		192
14. Review of Protocol Amendments		14/V1.4	193-198
14.1	Purpose		194
14.2	Scope		194
14.3	Responsibility		194
14.4	Flowchart		194
14.5	Detailed instructions		194
	14.5.1	Manage the Amendment Documents/ Package	194

	14.5.2	Determine whether expedited or full review	195
	14.5.3	Send the documents to only assigned primary reviewers/full review and Chairperson of the IEC	195
	14.5.4	Expedited Review	196
	14.5.5	Full Review by the IEC	196
	14.5.6	Protocol Amendment Review Process	196
	14.5.6.1	Review amended protocols	196
	14.5.7	Notify the Principal Investigator	196
	14.5.8	Updating the amendments in the database and Store documents	197
14.6	Annexures		197
AF/01/14/V1.4	Document History		198
15. Continuing Review and Extension of Study Protocol			15/V1.5
15.1	Purpose		199-203
15.2	Scope		200
15.3	Responsibility		200
15.4	Flowchart		200
15.5	Detailed Instructions		201
	15.5.1	Timeline for Submission	201

	15.5.2	Manage documents upon receipt	202
	15.5.2.1	Initial and date on the submitted documents	202
	15.5.2.2	Verify the contents of the document	202
	15.5.2.3	Store the continuing review document	202
	15.5.2.4	Notify and provide the document to the Member Secretary and assigned reviewer	202
	15.5.2.5	Place it in the IEC meeting Agenda	202
	15.5.3	Protocol continuing review process during IEC meeting	202
	15.5.4	Approval of minutes by the Chairperson	202
	15.5.5	Provide decision	202
15.6	Annexure		203
AF/01/15/V1.3	Document History		203
16. Review of Completion/Final Report			16/V1.4
16.1	Purpose		204-206
16.2	Scope		205
16.3	Responsibility		205
16.4	Flow Chart		205
16.5	Detailed Instructions		205

	16.5.1	Before each EC meeting	205	
	16.5.2	During the EC meeting	205	
	16.5.3	After each EC meeting	206	
16.6	Annexures		206	
AF/01/16/V1.4	Document History		206	
17. Management of study Termination / Suspension/ Discontinuation			17/V1.4	207-210
17.1	Purpose			208
17.2	Scope			208
17.3	Responsibility			208
17.4	Flow Chart			208
17.5	Detailed Instructions			208
	17.5.1	Receive recommendation for study termination		208
	17.5.2	Review and discuss the Termination Package		208
	17.5.3	Notify the Principal Investigator		208
	17.5.4	Store the protocol documents		208

	17.5.6	Inactivate the protocol documents	208
17.6	Annexure		209
AF/01/17/V1.4	Document History		210
I	Monitoring and Evaluation of Adverse Events		
18. Review of Adverse Events (AE) & Serious Adverse Events (SAE) Reports		18/V1.5	211-227
18.1	Purpose		212
18.2	Scope		212
18.3	Responsibility		212-213
18.4	Flow Chart		214
18.5	Detailed Instructions		215
	18.5.1	Before each IEC meeting	215
	18.5.1.1	Review and determine the review channel	215
	18.5.1.2	Criteria for the review	215
	18.5.2	During the IEC meeting	215
	18.5.2.1	Review and discuss	215
	18.5.2.2	Decide what action should be taken	215
	18.5.2.3	Inform investigator or clinical trial office	216

18.6	Annexures	216
AF/01/18/V1.5	AE Summary Report	217
AF/02/18/V1.5	SAE reporting format (Biomedical Health Research)	218-220
AF/03/18/V1.5	SAE reporting format (Clinical Trials)	221-223
AF/04/18/V1.5	Checklist for Submission of Serious Adverse Event Report (SAE) Occurring in Clinical Trial/ Bio- Equivalence Study	224-226
AF/05/18/V1.5	Document History	227
J	Monitoring Protocol Implementation	
19. Intervention in Protocol Deviation/Violation /Non-compliance	19/V1.4	228-237
19.1	Purpose	229
19.2	Scope	229
19.3	Responsibility	229
19.4	Flow Chart	229
19.5	Detailed instructions	229
	19.5.1 Definitions	230
	19.5.2 Noting the protocol deviation /violation/non-compliance reports	231
	19.5.3 Categorize the protocol deviations	231
	19.5.4 Review process	232

	19.5.5	Record and communicate the decision to the PI	233
19.6	Annexures		234
AF/01/19/V1.4	Protocol Violation/Deviation Reporting Form (Reporting by case)		234-236
AF/02/19/V1.4	Document History		237
20. Response to Research Participant`s Requests/queries/complaints		20/V1.3	238-243
20.1	Purpose		239
20.2	Scope		239
20.3	Responsibility		239
20.4	Flow Chart		239
20.5	Detailed instructions		239
	20.5.1	Receive the request	239
	20.5.2	Take action	240
	20.5.3	File the requested document	241
20.6	Annexure		241
AF/01/20/V1.3	Request Record Form		242
AF/02/20/V1.3	Document History		243
K	Site Monitoring		

21. Site Monitoring Visit		21/V1.5	244-250
21.1	Purpose		245
21.2	Scope		245
21.3	Responsibility		245
21.4	Flow Chart		245
21.5	Detailed instructions		245
	21.5.1	Selection of study sites	245
	21.5.2	Before the visit	246
	21.5.3	During the visit	246
	21.5.4	After the visit	246
	21.5.5	Expenditure for the site visit	247
21.6	Annexure		247
AF/01/21/V1.5		Checklist of a Monitoring Visit	248-249
AF/02/21/V1.5		Document History	250
L	Preparation of Review Meeting Agenda and Communication Records		
22. Agenda preparation, Meeting Procedures and Minutes		22/V1.5	251-261
22.1	Purpose		252
22.2	Scope		252

22.3	Responsibility	252
22.4	Flow Chart	252
22.5	Detailed instructions	252
	22.5.1 Before each Ethics Committee meeting	252-253
	22.5.2 During Ethics Committee Meeting	254
	22.5.3 Preparing the minutes and approval letters	255
22.6	Annexures	256
AF/01/22/V1.5	Format of an Agenda	257-259
AF/02/22/V1.5	Format of IEC Meeting Minutes	260
AF/03/22/V1.5	Document History	261
M	Managing Study Files	
23. Maintenance of active study files		23/V1.2 262-265
23.1	Purpose	263
23.2	Scope	263
23.3	Responsibility	263
23.4	Flow Chart	263
23.5	Detailed instructions	263
	23.5.1 Organize the contents of the active study files	263

	23.5.2	Maintain the active study files	264
23.6	Annexures		264
AF/01/23/V1.2	Document History		265
24. Archival and Retrieval of Documents			24/V1.2 266-271
24.1	Purpose		267
24.2	Scope		267
24.3	Responsibility		267
24.4	Flow Chart		267
24.5	Detailed instructions		267
	24.5.1	After receiving the final report	267
	24.5.2	When archiving administrative documents	267
	24.5.3	Retrieving Documents	268
24.6	Annexure		268
AF/01/24/V1.2	Document Request Form		269
AF/02/24/V1.2	Log of Requested IEC Documents		270
AF/03/24/V1.2	Document History		271
25. Maintaining Confidentiality of IEC Documents			25/V1.2 272-278
25.1	Purpose		273

25.2	Scope	273
25.3	Responsibility	273
25.4	Flow Chart	273
25.5	Detailed instructions	273
	25.5.1	Access to IEC Documents
	25.5.1.1	Members and Member Secretary of the IEC
	25.5.1.2	Secretariat of the IEC
	25.5.2	Classify confidential documents
	25.5.3	Copy confidential documents
	25.5.3.1	Copy Authorization
	25.5.3.2	Log of copies
	25.5.3.3	Copies requested by non-members of the IEC
	25.5.3.4	File Log of Copies
25.6	Annexure	275
AF/01/25/V1.2	Log of Requests for Copies of IEC's Documents	276
AF/02/25/V1.2	Log of Copies of Original Documents	277
AF/03/25/V1.2	Document History	278
N	Evaluating an IEC	

26. Audit and Inspection		26/V1.2	279-283
26.1	Purpose		280
26.2	Scope		280
26.3	Responsibility		280
26.4	Flow Chart		280
26.5	Detailed instructions		280
	26.5.1	Receive a Call for an Audit / Inspection	280
	26.5.2	Prepare for the audit / Inspection	280
	26.5.3	During the Audit / Inspection	281
	26.5.4	Discuss the Issues	281
	26.5.5	Record the Audit/Inspection Event	281
26.6	Annexure		281
AF/01/26/V1.2	Audit and Inspection Checklist		283
AF/01/26/V1.2	Document History		283
O	Review during Emergency		
27. Review process during Emergency		27/V1.1	284-292
27.1	Purpose		285
27.2	Scope		285

27.3	Responsibility	285
27.4	Informed Consent	285
	27.4.1 Informed Consent Process	285
	27.4.2 Electronic consent	286
	27.4.3 Waiver of consent	286
27.5	Ethical Review Procedures	286
	27.5.1 Ethics committee	286
	27.5.2 Ethics Review	287
27.6	Flow Chart	288-289
27.7	Review of Multi-center Research	290
27.8	Continuing Review & Monitoring	290
27.9	Decisions Regarding Other Studies:	290
27.10	Review of new non-emergency related research	291
27.11	Annexure	292
AF/01/27/V1.1	Document History	292

LIST OF ABBREVIATIONS

Acronym	Full Title/Description
AAHRPP	Association for the Accreditation of Institutional Research Protection Programs
ADR	Adverse Drug Reaction
AE	Adverse Event
BARC	Bhabha Atomic Research Centre
BE	Bio-equivalence
BIS	Bureau of Indian Standards
CDC	Center for Disease Control and Prevention
CDSCO	Central Drugs Standard Control Organization
CFR	Code of Federal Regulations
CIOMS	Council for International Organizations of Medical Sciences
CoI	Conflict of Interest
CONSORT	Consolidated standards of reporting trials

CRF	Case Record Form
CRO	Contract Research Organization
CTA	Clinical Trial Agreement
CTRI	Clinical Trial Registry of India
DAE	Department of Atomic Energy
DBT	Department of Biotechnology
DCGI	Drug Controller General of India
DCR	Drugs and Cosmetic Rules, 1945
DGFT	Directorate General of Foreign Trade
FDA	Food and Drug Administration
FDC	Fixed-Dose Combination
FERCAP	Forum for Ethical Review Committees in Asia and the Western Pacific Region
GCP	Good Clinical Practice
GEAC	Genetic Engineering Approval Committee

GLP	Good Laboratory Practices
GMP	Good Manufacturing Practices
HIPAA	Health Insurance Portability and Accountability Act
HMSC	Health Ministry Screening Committee
IAEA	International Atomic Energy Agency
IB	Investigator's Brochure
IBSC	Institutional Bio Safety Committee
IEC	Institutional Ethics Committee
ICF	Informed Consent Form
ICH	International Committee on Harmonization
ICMR	Indian Council of Medical Research
IC-SCR	Institutional Committee for Stem Cell Research
IDE	Investigational Device Exemption
IMDRA	Indian Medical Devices Regulatory Authority

IND	Investigational New Drug
IRB	Institutional Review Board
ISI	Indian Standards Institute
MoU	Memorandum of Understanding
MTA	Material Transfer Agreement
NAC-SCRT	National Apex Committee for Stem Cell Research and Therapy
NDA	New Drug Application
NIH	National Institutes of Health
NOC	No-objection Certificate
OHRP	Office for Institutional Research Protections
PI	Principal Investigator
PIS	Participant Information Sheet
RCGM	Review Com-mittee on Genetic Manipulation
RCT	Randomized Controlled Trial

SAE	Serious Adverse Event
SOPs	Standard Operating Procedures
SRC	Scientific Review Committee
WHO	World Health Organization
WMA	World Medical Assembly

BIBLIOGRAPHY

1. International Conference on Harmonization, Guidance on Good Clinical Practice (ICH GCP) 1996.
2. World Health Organization, Operational Guidelines for Ethics Committees that Review Biomedical Research, 2000.
3. WHO Operational Guidelines for Ethical Review Committee That Review Biomedical Research (Geneva 2000)
4. Ethical Guidelines for Biomedical Research on Human Participants, ICMR, 2006
5. WHO Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants, 2011
6. Declaration of Helsinki 2013
7. Draft Guidelines on Audio-Visual Recording of Informed Consent Process in Clinical Trial, CDSCO, MOHFW, 9th Jan 2014
8. ICH GCP E6(R2) Good Clinical Practice: Consolidated Guidance, 2016
9. Council for International Organizations of Medical Sciences 2016
10. Guidance for managing Ethical Issues in Infectious Disease outbreaks (WHO-2016).
11. National Ethical Guidelines for Biomedical and Health Research involving Human Participants, ICMR, 2017.
12. National Ethical Guidelines for Biomedical Research Involving Children, ICMR 2017
13. ICMR Stem cell 2017
14. ICMR common forms for ethical review, 2018.
15. US revised Common Rules 2019
16. New Drugs Clinical Trial Rules 2019
17. SIDCER FERCAP meeting minutes template, 2020
18. SIDCER FERCAP Agenda template, 2020
19. SIDCER FERCAP Assessment form template, 2021
20. Guidelines for usage of leftover De-identified/ Anonymous Samples for Commercial purposes, 2023
21. Guidance on Ethical requirements for Laboratory validation testing, 2024

- 22. Ethical requirements for systematic review and meta-analysis proposals,2024 (An addendum to ICMR National Ethical Guidelines for Biomedical and Health Research involving Human Participants 2017)**
- 23. Ethical Considerations for submission of Research Data to the ICMR Data center, May 2024**
- 24. Dissolving the National Apex Committee for Stem Cell Research and Therapy issued by the Department of Health Research, March 2024**

GLOSSARY

Active Study File	Any approved protocol, supporting documents, records containing communications and reports that correspond to each currently approved study
Administrative Documents	Documents include official minutes of IEC meetings and the Standard Operating Procedures, both historical files and Master Files
Agenda	A list of things to be done; a program of business at a meeting
Amendment protocol	A package of the amended parts and related documents of Package, the protocol, previously approved by the IEC. During the study, the Principal Investigator may decide to make changes in the protocol.
Approved Protocols	Protocols that have been <i>approved without stipulations</i> or <i>approved with recommendations</i> by the IEC may proceed. Protocols that have been <i>approved with stipulations</i> by the IEC may not proceed until the conditions set by the IEC in the decision have been met. Protocols should be amended and submitted to the IEC within <i>one</i> month for re-review.
Audit	A systematic and independent examination of research trial approval activities and documents to determine whether their view and approval activities were conducted and data were recorded and accurately reported according to the SOPs, GCP, Declaration of Helsinki and applicable regulatory requirements
Clinical trial office	An institute or an office where the study takes place and where the principal investigator and/or his/her staff may be reached
Conference	A meeting of individuals or representatives of various organizations to discuss and/or act on topics of common interest.
Confidentiality	Prevention of disclosure, to other than authorized individuals, of IEC/IRB's information and documents

<p>Confidentiality Agreement (Secrecy or Nondisclosure agreements)</p>	<p>An agreement designed to protect, information, data and expertise from being misused by those who have learned about them. The type of information that can be included under the umbrella of confidential information is virtually unlimited. Most confidentiality agreements exclude certain types of information from the definition of confidential information. The recipient must include these exceptions in the confidentiality agreement. An important point that must be covered in any confidentiality agreement is the standard by which the parties will handle the confidential information. The agreement must establish a time period during which disclosures will be made and the period during which confidentiality of the information is to be maintained.</p>
<p>Conflict of Interest</p>	<p>A situation in which a person, such as a public official, an employee, or a professional, has a private or personal interest sufficient to appear to influence the objective exercise of his or her official duties.</p> <p>Conflict of interest is present and interferes with the ability to make an objective evaluation when ethics committee members</p> <p>Have their research projects under review by the Ethics Committee, when they are an investigator, co-investigator, or when they are in a supervisory or mentoring relationship with a Principal Investigator.</p> <p>Members whose spouse/relative is a Principal Investigator or co-investigator, for any project under review are also considered to have a conflict of interest.</p> <p>Members may also have conflict of interest situations when they have interpersonal or financial relationships with the researchers, or personal or financial interests in a company, or organization that may be the sponsor of the research project, or that may be substantially affected by the research.</p> <p>To maintain the independence and integrity of research ethics review, members must identify, eliminate, minimize or otherwise manage real, potential or perceived conflicts of interest.</p> <p>If a member has a personal or financial conflict of interest the members must disclose the nature of the conflict and absent themselves from any discussion or decision regarding that research project. If a member's conflict of interest and necessary withdrawal from the meeting will threaten the maintenance of quorum, the Committee can ensure that an alternate member is in attendance to maintain quorum. There are three key elements in this definition: financial interest; official duties; professional and personal interest.</p>

Conflict of interest occurs when	<ol style="list-style-type: none"> 1. An individual's private interest differs from his or her professional obligations to the institute. 2. Professional actions or decisions occur that an independent observer might reasonably question. 3. A conflict depends upon the situation and not on the character or actions of the individual. 4. Potential conflicts of interest must be disclosed and managed as per policy.
CRF	Case Record Form or Case Report Form is a printed, optical, or electronic document designed to record all of the protocol-required information to be reported to the sponsor on each trial participant.
Deviation / Non - compliance / Violation	The IEC monitors whether investigators do not perform the study in compliance with the approved protocol, ICH GCP, national and international guidelines or regulations, and/or fail to respond to the IEC request for information/action.
Document	<p>Documents mean the following:</p> <ul style="list-style-type: none"> - Study Protocols and related documents (such as case report forms, informed consents, diary forms, scientific documents, reports, records, expert opinions or reviews) - IEC documents (SOPs, meeting minutes, advice and decisions) - Correspondence (experts, auditors, study participants, etc.) of any forms, such as printed or written papers, hard copies, electronic mails (e-mail), faxes, audio or video tapes, etc.
Expedited approval	An IEC approval granted only by the Chairman & assigned EC members of the IEC (not the full Board) for minor changes to new/ current IEC approved research activities and for research which involves not more than minimal risk.
ICD	Informed Consent Document is a written, signed and dated paper confirming participant's willingness to voluntarily participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the participant's decision to participate

IEC	Institutional Ethics Committee is an independent body (either a review board or committee) whose responsibility is to ensure the protection of the rights, safety, and well-being of human participants involved in a trial and to provide public assurance of that protection.
IEC members	Individuals serving as regular and alternate members of the institute's Ethical Committee. These committees are constituted in accordance with the EC membership requirements outlined in ICH GCP.
IEC representatives	Many IECs rarely find time to perform monitoring visits themselves. They may ask outside experts or the staff of Ethics Committees to perform the tasks on their behalf and later report their findings to IEC
Inactive Study Files	Approved and supporting documents (protocols, protocol amendments, informed consents, advertisements, investigator and site information), records containing communications and correspondence with the investigator, and reports (including but not limited to Continuing Review Reports, IND Safety Reports, reports of injuries to participants, scientific evaluations) that correspond to each study approved by the NIRRCH Ethics Committee for Human Studies for which a final report has been reviewed and accepted.
IND	Investigational New Drug is a drug that has never been seen in the market because it is under investigation for its efficacy and safety and has not yet been approved for marketing by the local authorities. The drug is therefore approved for use only at certain study sites
Independent Consultant	An expert who provides advice, comments and suggestions after reviewing study protocols without any affiliation to the institutes or investigators proposing the research.
Inspection	The act by some regulatory authorities of conducting an official review of documents, facilities, records, and any other resources that are deemed by the authorities to be related to the clinical trial and that may be located at the site of the trial, at the sponsor's and/or contract research organizations (CRO) facilities, Office of Ethics Committees, or at other establishments deemed appropriate by the regulatory authorities

Legally Authorized Representative (LAR)	A LAR is an individual or judicial or other body authorized under applicable law to consent on behalf of a prospective participant to participate in research or to undergo a diagnostic, therapeutic, or preventive procedure as per research protocol.
Majority vote	A Consensus procedure is carried out if one-half plus one member of the required quorum votes in its favor.
Master file	A file for storage of the originally signed and dated documents
Master SOP files	An official collection of the institute's standard operating procedures (SOP) accessible to all staff, IEC members, auditors and government inspectors as a paper copy with an official stamp on first and last page and the approval signatures. Photocopies made from these official paper versions of the SOP cannot be considered official.
Meeting	Deliberations between at least three (3) persons where such deliberations determine or result in the joint conduct or disposition of business.
Minutes	An official record of the business discussed and transacted at a meeting, conference, etc.
Monitoring visit	An action is that IEC or its representatives visit study sites to assess how well the selected investigators and the institutes are conducting research, taking care of participants, recording data, and reporting their observations, especially serious adverse events found during the studies. Normally monitoring visits will be arranged in advance with the principal investigators.
Non-members of the IEC	Any relevant person/persons who presently is/are not a member/members of the IEC such as authorities, monitors, auditors, participants, etc.
Project Review Form	An official record that documents the review process for Revised & Amendment Protocols as well as Continuing Review of approved protocols, Completion/ Final reports & Translated versions of Informed consent forms.
Quorum	Number of IEC members required to act on any motion presented to the Board for action.

Scientists	Professionals with advanced training and expertise in the medical or non-medical areas related to the protocol being reviewed
SOP historical files	A collection of previous official versions of a SOP, table of contents, relevant information regarding changes and all pre-planned deviations.
SOP Team	A selected committee of the members of ICMR-NIRRH Ethics Committee who oversee the creation, preparation, review and periodic revision of the institute's SOPs.
SOP (Standard Operating Procedure)	<p>Detailed, written instructions, in a certain format, describe all activities and actions undertaken by an organization to achieve uniformity in the performance of a specific function.</p> <p>The aim of the SOPs and their accompanying checklists and forms is to simplify the organization and documentation of operation, whilst maintaining high standards of Good Clinical Practice.</p>
Strategies to Manage Conflict of Interest	<ol style="list-style-type: none"> 1. Disclose conflict of interest 2. Document the conflict of interest in the attendance register and minutes of the meeting 3. Refrain from taking part in any discussion/review/ debate about the proposal; 4. Refrain from participating in the review process of the project proposal by leaving the meeting room.
Study Assessment Form	An official record that documents the protocol review process.
Vulnerability	The Council for International Organizations of Medical Sciences (CIOMS) defines vulnerability as persons who are vulnerable because they are relatively (or absolutely) incapable of protecting their interests.

Vulnerable (research) participants	Vulnerable persons are those who are relatively (or absolutely) incapable of protecting their own interests. More formally, they may have insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests. Individuals whose willingness to volunteer in a research study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate may also be considered vulnerable. (WHO)
Workshop	A group of people engaged in study or work on a creative project or subject





Institutional Ethics Committee

ICMR – National Institute for Research in Reproductive & Child Health

(SOPs, IEC)

**Codes: 01 / V1.6, 02 / V1.5, 03 / V1.3, 04 / V1.2, 05 / V1.2, 06 / V2.2,
07 / V1.5, 08 / V1.4, 09 / V1.7, 10 / V1.1, 11 / V3.4, 12 / V2.1,
13 / V1.4, 14 / V1.4, 15 / V1.5, 16 / V1.4, 17 / V1.4, 18 / V1.5,
19 / V1.4, 20 / V1.3, 21 / V1.5, 22 / V1.5, 23 / V1.2, 24 / V1.2,
25 / V1.2, 26 / V1.2, 27 / V1.1**

Prepared by SOP Team:


Name and Position on the IEC	Signature with date
Dr. Vikrant Bhor Member Secretary	 8/11/2024
Dr. Bhakti Pathak Joint Member Secretary	 8/11/2024
Dr. Sandeep Bavdekar EC Member (Non- Affiliated)	 8/11/2024
Dr. Rakhi Tripathi EC Member (Non- Affiliated)	 8/11/2024

Members of the Institutional Ethics Committee:


Sr.No	Name	Qualification with Specialization	Current Organization	Designation / Role of member in Ethics Committee	Affiliation of member with institute that has constituted the Ethics Committee
1.	Dr. Shubhada Chiplunkar	MSc, Ph.D, (Cancer Research)	Former Director ACTREC-TMC Kharghar Navi Mumbai	Chairperson	Non - Affiliated
2.	Dr. Vikrant Bhor	MSc Life Science, Ph.D	Scientist-E Head of Department (Molecular Immunology Microbiology) ICMR – National Institute for Research in Reproductive and Child Health J. M. street Parel Mumbai -12	Member Secretary Basic Scientist	Affiliated
3	Dr. Bhakti Pathak	MSc, Ph.D (Life Sciences)	Scientist-F Head of Department (Cellular and Structural Biology Division) ICMR – National institute for Research in Reproductive Child Health J. M. street Parel Mumbai -12	Joint Member Secretary Basic Scientist	Affiliated
4.	Dr. Yogeshwar Nandanwar	MBBS, M.D. Obstetrics and Gynecology	Professor (Obstetrics and Gynecology) D.Y. Patil Medical College & Research Centre , Mumbai	Clinician	Non - Affiliated
5.	Dr. Sandeep Bavdekar	MBBS, MD Diploma in Child Health, Certificate in Hospital & Health Care Management	Ex-Professor & Head Pediatrics Department, BYL Nair Charitable Hospital & T.N Medical College Mumbai	Pediatrician	Non - Affiliated
6.	Dr. Sivakami Muthusamy	Ph.D and Population Studies	Professor & Chairperson. Center for Health and Social Sciences. School of Health System Studies. Tata Institute of Social Sciences, V.N. Purav Marg. Deonar Mumbai -400088	Social Scientist	Non - Affiliated
7.	Dr. Ketki Kulkarni	MBBS, M.D. Obstetrics and Gynecology	Ex - Assistant Professor in OB GY, Nowrosjee Wadia Maternity Hospital, Mumbai Consultant Obstetrician and Gynecologist and Foetal Medicine Specialist.	Clinician	Non - Affiliated
8.	Dr. Rakhi Tripathi	MBBS, MD (Pharmacology)	Associate Professor Dept of pharmacology & Therapeutics Seth G.S. Medical College & KEM hospital, Parel, Mumbai-12	Pharmacology Expert	Non - Affiliated

9.	Dr. Bipin Kulkarni	MSc Life Science, Ph.D	Scientist-E Head, Department of Hemostasis and Thrombosis ICMR-NIIH, Mumbai-12	Basic Scientist	Non - Affiliated
10.	Mrs. Sudha Sathaye	B. com Bussiness Graduation by Goldman Sach	Sole Proprietorship Bussiness	Community Person	Non - Affiliated
11.	Dr. K.V. Ganpathy	Masters In Human Resource Management, TISS Ph.D (MSW)	Chief Executive Officer (Jeet Association for Support to Cancer Patients)	Community Person	Non - Affiliated
12.	Adv. Ajay Shinde	BSc (Chemistry), D.Pharm, LL.B	Independent Lawyer	Legal Expert	Non – Affiliated
13.	Dr. Shailesh Pande	MBBS, MS (Anatomy)	Scientist-E Head of Department (Genetic Research Centre) ICMR – National institute for Research in Reproductive Child Health J. M. street Parel Mumbai -12	Clinician	Affiliated
14	Dr. Sadhana Gupta	MSc, Ph.D (Life Sciences)	Scientist-D Head of Department (Infectious Disease) ICMR – National institute for Research in Reproductive Child Health J. M. street Parel Mumbai -12	Basic Scientist	Affiliated

Approved By:

Name and Position on the IEC	Signature with date
Prof. Shubhada Chiplunkar (Chairperson, IEC)	 CHAIRPERSON

Accepted by:

Name and Position on the IEC	Signature with date
Dr. Geetanjali Sachdeva, Director, ICMR – NIRRH	 8/11/2024 डॉ. गीतानजलि सचदेवा/Dr. Geetanjali Sachdeva निदेशक/Director आई.सी.एम.आर.-राष्ट्रीय प्रजनन एवं बाल स्वास्थ्य अनुसंधान संस्थान ICMR-National Institute for Research in Reproductive and Child Health जहांगिर मेरवानजी पथ, /Jehangir Merwanji Street, परेल, मुंबई - 400012/Parel, Mumbai-400 012